Key result
TAVR significantly improved quality of life at 6 months in patients with severe aortic stenosis, increasing the SF-12 Physical Component Summary score from 30.1 to 37.0 (p<0.001).
Why the study?
Does TAVR improve quality of life in elderly patients with severe aortic stenosis at high or extreme surgical risk?
Observational (n=71)
No
Does TAVR improve quality of life in elderly patients with severe aortic stenosis at high or extreme surgical risk?
Absolute Event Rate: 37% vs 30.1%
p-value: p=<0.001
TAVR in patients with severe aortic stenosis at high surgical risk is associated with significant early improvements in both physical and mental components of quality of life at 6 months.
May support TAVR consideration for QoL in elderly AS; leaves open need for confirmatory randomized trials.
Background: Transcatheter aortic valve replacement (TAVR) is the recommended therapy for patients with severe calcific aortic stenosis (AS) who are not suitable candidates for surgery.The aim of this study is to evaluate the quality of life (QOL) for patients with severe AS with extreme and high surgical risk following TAVR with the Core Valve Medtronic prosthesis.Methods: An analysis of patients who underwent TAVR with the Medtronic self-expanding Core Valve system (Medtronic, Inc.) at the University of Miami hospital was conducted between April 2011, and March 2014.Demographic and clinical data were obtained from inpatient and outpatient clinical records.QOL assessment was realized with the SF-12 Health-Survey.The questionnaire was administered at baseline, 6 months and 1 year after TAVR.Missing values were treated with median based imputation.Results: A total of 71 patients underwent TAVR therapy.Of these, 63 patients successfully completed or partially completed the SF-12 questionnaire at 6 months follow up.Mean age was 85.0 ± 8.2 years and 65% were male.Eight patients (11.3%) died during follow up.After 6 months, a significant improvement in both scores (PCS 37.0; p < 0.001 and MCS 52.5 p < 0.001) was observed.Conclusions: The main finding of this study is that TAVR in patients with severe AS is followed by early improvements in quality of life.The results show a marked improvement in functional status and a significant improvement in quality of life in both physical and mental components.
No takes yet. Share an insight, caveat, or question.
Yaar Aga (2016) conducted an observational in Severe calcific aortic stenosis (n=71). Transcatheter Aortic Valve Replacement (TAVR) vs. Baseline was evaluated on SF-12 Physical Component Summary (PCS) score at 6 months (p=<0.001). TAVR significantly improved quality of life at 6 months in patients with severe aortic stenosis, increasing the SF-12 Physical Component Summary score from 30.1 to 37.0 (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: